Lipocine IncLPCN
Price$2.07

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $1.6M-86.0% YoYTTM through 30 Jun 2026
Net Income -$11.9M-141,999.0% YoYTTM through 30 Jun 2026
Free Cash Flow -$11.3MTTM through 30 Jun 2026

Margins

Current
EBITDA Margin-797.1%
Operating Margin-520.0%
Net Margin-755.1%

Returns

-66.3%ROE
-56.5%ROA

Balance Sheet Health

Debt / Equity0.02x
Current Ratio11.48x
Net Debt-$14.7Mnet cash position
Cash & Equivalents$5M

Quality Metrics

Altman Z-Score-8.09
Piotroski F-Score2 / 9
FCF Margin-718.8%
Earnings-Beat Rate25.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $2M
Diluted EPS-$1.77TTM
'19'20'21'22'23'24'25
FY2025: $-1.69

Dividend

No dividend

Capital Allocation

Capex Intensity5.7%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.